The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors

Fernando E. Membreno; Eric J. Lawitz

doi:10.1016/j.cld.2011.05.003

The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors

Fernando E. Membreno, Eric J. Lawitz

Research output: Contribution to journal › Review article › peer-review

42 Scopus citations

Abstract

This article introduces one of the most diverse classes of direct-acting antivirals for hepatitis C, the nucleoside and non-nucleoside NS5B polymerase inhibitors. Through a systematic review of the published literature, we describe their structure, mechanism of action, issues with resistance, and clinical effectiveness shown in the latest clinical trials. Direct-acting antiviral combination trials that have already shown some early promising results even in the setting of interferon-sparing antiviral regimens are discussed.

Original language	English (US)
Pages (from-to)	611-626
Number of pages	16
Journal	Clinics in Liver Disease
Volume	15
Issue number	3
DOIs	https://doi.org/10.1016/j.cld.2011.05.003
State	Published - Aug 1 2011
Externally published	Yes

Keywords

Hepatitis C virus
Non-nucleoside inhibitors
NS5B nucleoside inhibitors
Polymerase inhibitors

ASJC Scopus subject areas

Hepatology

Access to Document

10.1016/j.cld.2011.05.003

Fingerprint Dive into the research topics of 'The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors'. Together they form a unique fingerprint.

Cite this

@article{9c58efc9848346e2993526612ba5c438,

title = "The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors",

abstract = "This article introduces one of the most diverse classes of direct-acting antivirals for hepatitis C, the nucleoside and non-nucleoside NS5B polymerase inhibitors. Through a systematic review of the published literature, we describe their structure, mechanism of action, issues with resistance, and clinical effectiveness shown in the latest clinical trials. Direct-acting antiviral combination trials that have already shown some early promising results even in the setting of interferon-sparing antiviral regimens are discussed.",

keywords = "Hepatitis C virus, Non-nucleoside inhibitors, NS5B nucleoside inhibitors, Polymerase inhibitors",

author = "Membreno, {Fernando E.} and Lawitz, {Eric J.}",

year = "2011",

month = aug,

day = "1",

doi = "10.1016/j.cld.2011.05.003",

language = "English (US)",

volume = "15",

pages = "611--626",

journal = "Clinics in Liver Disease",

issn = "1089-3261",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors

AU - Membreno, Fernando E.

AU - Lawitz, Eric J.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - This article introduces one of the most diverse classes of direct-acting antivirals for hepatitis C, the nucleoside and non-nucleoside NS5B polymerase inhibitors. Through a systematic review of the published literature, we describe their structure, mechanism of action, issues with resistance, and clinical effectiveness shown in the latest clinical trials. Direct-acting antiviral combination trials that have already shown some early promising results even in the setting of interferon-sparing antiviral regimens are discussed.

AB - This article introduces one of the most diverse classes of direct-acting antivirals for hepatitis C, the nucleoside and non-nucleoside NS5B polymerase inhibitors. Through a systematic review of the published literature, we describe their structure, mechanism of action, issues with resistance, and clinical effectiveness shown in the latest clinical trials. Direct-acting antiviral combination trials that have already shown some early promising results even in the setting of interferon-sparing antiviral regimens are discussed.

KW - Hepatitis C virus

KW - Non-nucleoside inhibitors

KW - NS5B nucleoside inhibitors

KW - Polymerase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=80052070428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052070428&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2011.05.003

DO - 10.1016/j.cld.2011.05.003

M3 - Review article

C2 - 21867940

AN - SCOPUS:80052070428

VL - 15

SP - 611

EP - 626

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 3

ER -